化学信息:
化学名
|
N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
|
|
简称
|
ABT-333
|
别名
|
Dasabuvir, ABT333, ABT 333
|
中文名
|
N/A
|
化学式
|
C26H27N3O5S
|
分子量
|
493.57
|
CAS号
|
1132935-63-7
|
纯度
|
98%
|
溶剂/溶解度
|
Water<1mg/ml; DMSO6mg/ml; Ethanol<1mg/ml
|
溶液配制
|
5mg加入1.01ml DMSO,或者每4.94mg加入1ml DMSO,配制成10mM溶液。SC3256-10mM用DMSO配制。
|
生物信息:
产品描述
|
ABT-333 is an NS5B non-nucleoside polymerase inhibitor.
|
信号通路
|
Anti-infection
|
靶点
|
HCV NS5B
|
-
|
-
|
-
|
-
|
IC50
|
-
|
-
|
-
|
-
|
-
|
体外研究
|
N/A
|
体内研究
|
All patients received ABT-333 (400mg twice daily) and ribavirin (1000 to 1200mg per day) and one of two daily doses of ABT-450/r. Groups 1 and 2 included previously untreated patients; group 1 received 250mg of ABT-450 and 100mg of ritonavir, and group 2 received 150mg and 100mg, respectively. Group 3, which included patients who had had a null or partial response to previous therapy with peginterferon and ribavirin, received daily doses of 150mg of ABT-450 and 100mg of ritonavir. An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection.
|
临床实验
|
N/A
|
特征
|
N/A
|
相关实验数据(此数据来自于公开文献,碧云天并不保证其有效性):
酶活性检测实验
|
方法
|
N/A
|
细胞实验
|
细胞系
|
N/A
|
浓度
|
N/A
|
处理时间
|
N/A
|
方法
|
N/A
|
动物实验
|
动物模型
|
N/A
|
配制
|
N/A
|
剂量
|
N/A
|
给药方式
|
N/A
|
参考文献:
1. Poordad F, et al. N Engl J Med. 2013 Jan 3, 368(1), 45-53.
2. Kowdley KV, et al. N Engl J Med. 2014 Jan 16, 370(3), 222-32.
包装清单:
产品编号
|
产品名称
|
包装
|
SC3256-10mM
|
ABT-333 (HCV抑制剂)
|
10mM×0.2ml
|
SC3256-5mg
|
ABT-333 (HCV抑制剂)
|
5mg
|
SC3256-25mg
|
ABT-333 (HCV抑制剂)
|
25mg
|
—
|
说明书
|
1份
|
保存条件:
-20℃保存,至少一年有效。5mg和25mg包装也可室温保存,至少6个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
注意事项:
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。